Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.66 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30149949 | 1.00 | ALDH1A1 (0.67) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL10807598 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL7646253 | 0.84 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL28000437 | 0.84 | PSMB8 (0.69) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL30732411 | 0.84 | PSMB8 (0.69) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL9636277 | 0.84 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL7905772 | 0.84 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL12344745 | 0.83 | ALDH1A1 (0.60) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL12344738 | 0.83 | ALDH1A1 (0.60) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL1505008 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPTLMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102070563-B | Method for preparing 2-benzothiazolylethyl sulfone | UNIV ZHEJIANG | 2012-06-06 | — | — | CN | claimed |
| US-5101034-A | Reaction of a sulfonylated heteroaromatic with an oxyacetamide; herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | claimed |
| EP-0165537-B1 | PROCESS FOR THE PREPARATION OF HETEROARYLOXYACETAMIDES | BAYER AG (DE) | 1990-01-17 | — | — | EP | claimed |
| EP-0165537-A2 | Process for the preparation of heteroaryloxyacetamides | BAYER AG (DE) | 1985-12-27 | — | — | EP | claimed |
| EP-1740559-B1 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-1740559-B1 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120169974-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120169974-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
| US-7847100-B2 | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Inc. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7847100-B2 | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Inc. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7847100-B2 | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Inc. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1740559-A4 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO INC (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2002040459-A1 | PREPARATION OF MONOFLUOROALKENES | BAYER CROPSCIENCE GMBH (DE) | 2002-05-23 | — | — | WO | disclosed |
| EP-0472975-B1 | Asymmetric dioxazine compounds and method for dyeing or printing fiber materials using the same | SUMITOMO CHEMICAL CO (JP) | 1997-12-17 | — | — | EP | disclosed |
| EP-0541084-B1 | Asymmetric dioxazine compounds and method for dyeing or printing fiber materials using the same | SUMITOMO CHEMICAL CO (JP) | 1997-02-26 | — | — | EP | disclosed |
| US-5101034-A | Reaction of a sulfonylated heteroaromatic with an oxyacetamide; herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | disclosed |
| EP-0165537-B1 | PROCESS FOR THE PREPARATION OF HETEROARYLOXYACETAMIDES | BAYER AG (DE) | 1990-01-17 | — | — | EP | disclosed |
| EP-0165537-A2 | Process for the preparation of heteroaryloxyacetamides | BAYER AG (DE) | 1985-12-27 | — | — | EP | disclosed |
| EP-0044497-B1 | PROCESS FOR THE PRODUCTION OF HETEROCYCLIC SUBSTITUTED DERIVATIVES OF 4-OXYPHENOXY-ALKANE-CARBONIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-11-28 | — | — | EP | disclosed |
| EP-0044497-A2 | Process for the production of heterocyclic substituted derivatives of 4-oxyphenoxy-alkane-carbonic acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120169974-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | LASP1, TBRG4, CALCOCO2 | ALDH1A1 4768/4885MAPT 59/4885LMNA 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.